GRAIL, Inc.

Company Overview

GRAIL, Inc. (Nasdaq: GRAL) is a U.S.-based healthcare and biotechnology company focused on multi-cancer early detection (MCED) using blood-based genomic screening technologies. The company operates within the precision medicine, molecular diagnostics, and oncology screening industries. Its core business centers on detecting cancer signals through next-generation sequencing and machine learning analysis of cell-free DNA in blood samples, with the goal of identifying cancers before symptoms emerge. GRAIL’s primary commercial product is the Galleri blood test, which is designed to screen for multiple cancer types through a single blood draw. Revenue is primarily generated through test sales, healthcare partnerships, and collaborations related to cancer screening and clinical research.

GRAIL was originally founded in 2015 as a spinout backed by Illumina, Inc. and several technology and healthcare investors. The company developed its platform around high-intensity genomic sequencing and large-scale clinical data analysis. In 2021, Illumina completed an acquisition of GRAIL despite ongoing antitrust scrutiny in the United States and Europe. Following regulatory disputes and divestiture proceedings, Illumina completed the separation of GRAIL into an independent publicly traded company in 2024. GRAIL’s strategic positioning is tied to its extensive clinical trial data, proprietary cancer detection algorithms, and early leadership in the emerging MCED screening category.